new studies on glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Weight loss with GLP-1 medicines

Substance-use disorders Pre-clinical and mechanistic studies A large body of pre-clinical and mechanistic literature is available regarding the putative effects of GLP-1RAs on substance misuse (Supplementary Section 5): 24 for alcohol 59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82 , 8 for opiates 63,83,84,85,86,87,88,89 , 16 for stimulants, including cocaine and amphetamines 90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105 , and 4 for nicotine 106,107,108,109

If it doesnt taste good or blend well, you wont use it

The medications most commonly associated with this issue include semaglutide (sold as Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), retatrutide , and oral GLP-1 formulations

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Also, obesity hurts the heart, kidneys, liver, and mental health

[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Ishihara Y., Nishiguchi S., Branch J., Tanaka E